Quick Takeaways
- Michael Thomas Heffernan has 8 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,595,427.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Michael Thomas Heffernan
- Location
- Wayne, PA
- Summary
- The estimated net worth of Michael Thomas Heffernan is at least $1,595,427 dollars as of 10 Jul 2025. Michael Thomas Heffernan is the Director of COLLEGIUM PHARMACEUTICAL, INC and owns shares of COLLEGIUM PHARMACEUTICAL, INC (COLL) stock worth about $1.54M. Michael Thomas Heffernan is the Director of Akebia Therapeutics, Inc. and owns shares of Akebia Therapeutics, Inc. (AKBA) stock worth about $59.4K.
- Signature
- /s/ Lee Giguere, as attorney-in-fact for the Reporting Person
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Michael Thomas Heffernan and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: COLLEGIUM PHARMACEUTICAL, INC ($1,536,011).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Michael Thomas Heffernan
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| COLL | COLLEGIUM PHARMACEUTICAL, INC | Director | $1,536,011 | 10 Feb 2025 | ||
| AKBA | Akebia Therapeutics, Inc. | Director | $59,416 | 02 Jun 2021 | ||
| AVTX | Avalo Therapeutics, Inc. | Director | 17 Jun 2025 | |||
| BHVN | Biohaven Ltd. | Director | 05 May 2025 | |||
| BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Director | 03 Oct 2022 | |||
| ENGN, ENGNW | enGene Holdings Inc. | Director | 08 Jul 2025 | |||
| SYBX | SYNLOGIC, INC. | Director | 22 Jun 2023 | |||
| TRVI | Trevi Therapeutics, Inc. | Director | 11 Jun 2025 |
Insider Transactions Reported by Michael Thomas Heffernan:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.